Literature DB >> 22562256

Impact and prognostic implications of colon cancers stage II sub-classification through the years.

Laura Lorenzon1, Emanuela Pilozzi, Marco La Torre, Vincenzo Ziparo, Mario Ferri.   

Abstract

PURPOSE: According to the American Joint Committee on Cancer (AJCC) 7th edition, T4 colon cancers have been sub-divided into T4a and T4b, resulting in a stage II sub-classification (T3N0, T4aN0, and T4bN0). This study was aimed: (a) to investigate the impact of the AJCC 7th edition stage II sub-classification on the overall survival (OS), disease-free survival (DFS) and disease-specific survival (DSS) of colon cancer patients who underwent surgical resection and (b) to compare the last three AJCC editions for identifying stage II patients with high-risk of progression.
METHODS: One hundred seventy-eight stage II colon cancers out of 682 colorectal cancer patients who underwent surgical resection were selected. T4N0 were sub-divided in accordance with the AJCC 7th edition. Mean follow-up was 41.9 months. Kaplan-Meier method was employed to estimate the survival curves.
RESULTS: OS analysis documented a significant difference between stage-sub-groups using the 6th edition; conversely, this difference was not seen if the 7th edition was applied (p = 0.03 and 0.12, respectively). Stage II DFS analysis reported a significant difference using both the AJCC 6th and 7th editions (p = 0.03 and 0.02, respectively). A significant difference was reported on stage II DSS analysis using the AJCC 6th edition (p = 0.03); however, when the 7th edition was applied, a substantial discrepancy between survival curves was noted with T3N0 and T4aN0 displaying similar outcomes (p = 0.006).
CONCLUSIONS: The AJCC 7th edition is a reliable classification that might implement the identification of those stage II colon cancer patients with high-risk of progression, recurrence, and cancer mortality.

Entities:  

Mesh:

Year:  2012        PMID: 22562256     DOI: 10.1007/s00384-012-1475-x

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  15 in total

1.  Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial.

Authors:  Francisco Rodríguez-Moranta; Joan Saló; Angels Arcusa; Jaume Boadas; Virgínia Piñol; Xavier Bessa; Eduard Batiste-Alentorn; Antonio M Lacy; Salvadora Delgado; Joan Maurel; Josep M Piqué; Antoni Castells
Journal:  J Clin Oncol       Date:  2005-12-19       Impact factor: 44.544

Review 2.  American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group.

Authors:  C Compton; C M Fenoglio-Preiser; N Pettigrew; L P Fielding
Journal:  Cancer       Date:  2000-04-01       Impact factor: 6.860

Review 3.  Radiation, chemotherapy and biological therapy in the curative treatment of locally advanced rectal cancer.

Authors:  S Gollins
Journal:  Colorectal Dis       Date:  2010-08       Impact factor: 3.788

Review 4.  Histopathological reporting of pT4 tumour stage in colorectal carcinomas: dotting the 'i's and crossing the 't's.

Authors:  R Swamy
Journal:  J Clin Pathol       Date:  2010-02       Impact factor: 3.411

5.  Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis.

Authors:  Leonard L Gunderson; Daniel J Sargent; Joel E Tepper; Michael J O'Connell; Cristine Allmer; Steven R Smalley; James A Martenson; Daniel G Haller; Robert J Mayer; Tyvin A Rich; Jaffer A Ajani; John S Macdonald; Richard M Goldberg
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-10-01       Impact factor: 7.038

6.  Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes.

Authors:  Leonard L Gunderson; John Milburn Jessup; Daniel J Sargent; Frederick L Greene; Andrew Stewart
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

7.  Revised TN categorization for colon cancer based on national survival outcomes data.

Authors:  Leonard L Gunderson; John Milburn Jessup; Daniel J Sargent; Frederick L Greene; Andrew K Stewart
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

Review 8.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.

Authors:  Al B Benson; Deborah Schrag; Mark R Somerfield; Alfred M Cohen; Alvaro T Figueredo; Patrick J Flynn; Monika K Krzyzanowska; Jean Maroun; Pamela McAllister; Eric Van Cutsem; Melissa Brouwers; Manya Charette; Daniel G Haller
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

9.  A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients.

Authors:  Frederick L Greene; Andrew K Stewart; H James Norton
Journal:  Ann Surg       Date:  2002-10       Impact factor: 12.969

10.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Authors:  Sharlene Gill; Charles L Loprinzi; Daniel J Sargent; Stephan D Thomé; Steven R Alberts; Daniel G Haller; Jacqueline Benedetti; Guido Francini; Lois E Shepherd; Jean Francois Seitz; Roberto Labianca; Wei Chen; Stephen S Cha; Michael P Heldebrant; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2004-04-05       Impact factor: 44.544

View more
  1 in total

1.  Comparison of Long-Term Survival Outcomes of T4a and T4b Colorectal Cancer.

Authors:  Ji Ha Lim; Jung Wook Huh; Woo Yong Lee; Seong Hyeon Yun; Hee Cheol Kim; Yong Beom Cho; Yoon Ah Park; Jung Kyong Shin
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.